Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/4/2018
SIETES contiene 92261 citas

 
 
 1 a 20 de 321 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Pennel PB. Prescribing antiepileptic drugs to women of reproductive age. Lancet Neurol 2018:1. [Ref.ID 102517]
2. Cita con resumen
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F, for the EURAP study group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018:1. [Ref.ID 102516]
3.Tiene citas relacionadas Cita con resumen
Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]
4. Cita con resumen
Pennell PB. Antiepileptic drugs in pregnancy — Quick decisions with long-term consequences. JAMA Neurology 2018:1. [Ref.ID 102464]
5. Cita con resumen
Elkjær LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurology 2018:1. [Ref.ID 102463]
6.Tiene citas relacionadas Cita con resumen
Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]
7. Cita con resumen
Bjørk M, Riedel B, Spiqset O, Veiby G, Kolstad E, Daltveit AK, Gilhus NE. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs In utero. JAMA Neurology 2017:26 de diciembre. [Ref.ID 102193]
8. Cita con resumen
Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 2017;318:1700-1. [Ref.ID 102140]
9. Cita con resumen
Anónimo. Acide valproïque et grossesse: évaluation des malformations en France. Prescrire 2017;37:513. [Ref.ID 102011]
10. Cita con resumen
Anónimo. Malformations congénitales chez les enfants exposés in utero au valproate et aux autres traitements de l’épilepsie et des troubles bipolaires - Communiqué. Agence Nationale de Sécurité des Médicaments et des Produits de Santé 2017:20 de abril. [Ref.ID 101537]
11. Cita con resumen
Anónimo. France establishes compensation fund for victims of epilepsy drug. DIA Daily 2016:1. [Ref.ID 100940]
12. Cita con resumen
Baftiu A, Landmark CJ, Rusten IR, Feet SA, Johannessen SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders - A pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol 2016;72:1245-54. [Ref.ID 100799]
13. Cita con resumen
Casassus B. Drug scandals in France: have the lessons been learnt?. Lancet 2016;388:550-2. [Ref.ID 100574]
14. Cita con resumen
Anónimo. Pérampanel et épilepsies généralisées réfractaires. Prescrire 2016;36:492-3. [Ref.ID 100550]
15. Cita con resumen
Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]
16.Tiene citas relacionadas Cita con resumen
Malhi GS. Lithium therapy in bipolar disorder: a balancing act?. Lancet 2015;386:415-6. [Ref.ID 99396]
17. Cita con resumen
Anónimo. Incontinences urinaires d'origine médicamenteuse. Prescrire 2015;35:271-4. [Ref.ID 99126]
18. Cita con resumen
Velez-Ruiz NJ, Meador KJ. Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Saf 2015;38:271-8. [Ref.ID 98950]
19. Cita con resumen
Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia. Number needed to harm . JAMA Psychiatry 2015;72:438-45. [Ref.ID 98861]
20.Enlace a cita original Cita con resumen
Anónimo. Medicines related to valproate: risk of abnormal pregnancy outcomes. Drug Safety Update 2015;8:1. [Ref.ID 98832]
Seleccionar todas
 
 1 a 20 de 321 siguiente >>